Ensysce Biosciences, Inc. (ENSC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.38. The rating moved from Strong Oversold to Oversold on August 15, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$0.38
• Last changeMoved from Strong Oversold to Oversold on August 15, 2026
• SectorHealthcare
• IndustryBiotechnology

See all oversold Healthcare stocks →

AI analysis

Ensysce Biosciences, Inc. (ENSC) is a small, development‑stage biotech with limited public disclosure and low liquidity. The company appears to rely on external capital and is highly sensitive to binary clinical, regulatory, or partnership events. There are no clear near‑term revenue drivers documented in the provided materials; upside requires positive trial readouts, licensing deals, or successful financing with acceptable dilution. Downside is driven by funding risk, possible clinical setbacks, and the amplified impact of low trading volume. Overall market tone is mildly risk‑on, but sector tailwinds described in broader healthcare themes are only indirectly relevant to the company’s near‑term prospects.

Key factors

• Micro‑cap / development‑stage profile with limited liquidity and public information
• Likely dependence on external financing; cash runway and dilution risk are material
• Binary event risk tied to clinical/regulatory milestones and licensing discussions
• No recent EDGAR/financial report comparison available in the provided data, increasing information asymmetry
• Broader healthcare sector themes (biologics/CDMO demand, payer analytics) provide mixed, indirect implications rather than direct near‑term catalysts
• Small float and low trading volume amplify volatility and downside on negative news

Risks

• Near‑term equity raises that materially dilute existing shareholders
• Clinical or regulatory setbacks for development programs
• Limited operating history or commercial revenue leading to negative cash flow
• Low liquidity causing exaggerated price swings and difficulty executing trades
• Competitive pressure from better‑funded peers and larger pharma partners
• Lack of timely public disclosures or filings that raise information risk
• Macro funding environment tightening could hamper access to capital

Latest MarketMoodz coverage

• Ensysce Biosciences surges as board launches strategic review2026-02-27

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.